Assignee
SCHOLAR ROCK INC
US·32 granted patents·32 pending applications·240 citations·filing 2013–2025
Top patents by PatentIndex Score
64 records- 0197US9580500B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2015·Granted Feb 28, 2017·36 cites·8 claims
- 0297US9573995B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2015·Granted Feb 21, 2017·41 cites·10 claims
- 0397US9399676B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2015·Granted Jul 26, 2016·38 cites·7 claims
- 0495US10597443B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2017·Granted Mar 24, 2020·16 cites·23 claims
- 0594US12006359B2Methods for altering body composition by administering anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2020·Granted Jun 11, 2024·3 cites·8 claims
- 0694US11827698B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2021·Granted Nov 28, 2023·2 cites·23 claims
- 0794US11439704B2Methods for using anti-myostatin antibodiesSCHOLAR ROCK INC·Filed 2020·Granted Sep 13, 2022·5 cites·12 claims
- 0894US10981981B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2018·Granted Apr 20, 2021·5 cites·24 claims
- 0994US10287345B2Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2017·Granted May 14, 2019·14 cites·11 claims
- 1094US9758576B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2015·Granted Sep 12, 2017·13 cites·10 claims
- 1194US9758577B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2016·Granted Sep 12, 2017·13 cites·16 claims
- 1292US11925683B2Compositions for making and using anti-Myostatin antibodiesSCHOLAR ROCK INC·Filed 2021·Granted Mar 12, 2024·2 cites·9 claims
- 1391US11135291B2Methods for making and using anti-myostatin antibodiesSCHOLAR ROCK INC·Filed 2019·Granted Oct 5, 2021·10 cites·26 claims
- 1491US10882904B2Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2019·Granted Jan 5, 2021·6 cites·19 claims
- 1591US10307480B2Anti-pro/latent-myostatin antibodies and uses thereofSCHOLAR ROCK INC·Filed 2015·Granted Jun 4, 2019·12 cites·19 claims
- 1690US12454570B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2023·Granted Oct 28, 2025·0 cites·19 claims
- 1790US10946036B2Use of myostatin inhibitors and combination therapiesSCHOLAR ROCK INC·Filed 2017·Granted Mar 16, 2021·6 cites·22 claims
- 1889US10751413B2Anti-pro/latent-Myostatin antibodies and uses thereofSCHOLAR ROCK INC·Filed 2016·Granted Aug 25, 2020·8 cites·11 claims
- 1988US11214614B2LTBP complex-specific inhibitors of TGFβ and uses thereofSCHOLAR ROCK INC·Filed 2020·Granted Jan 4, 2022·2 cites·3 claims
- 2088US11155611B2Compositions and methods for making and using anti-myostatin antibodiesSCHOLAR ROCK INC·Filed 2018·Granted Oct 26, 2021·5 cites·7 claims
- 2186US11365245B2LTBP complex-specific inhibitors of TGFβ and uses thereofSCHOLAR ROCK INC·Filed 2021·Granted Jun 21, 2022·1 cites·8 claims
- 2285US12122823B2Isoform-selective TGFB1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2021·Granted Oct 22, 2024·1 cites·13 claims
- 2383US2024391989A1Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2024·Application pending·0 cites
- 2482US2025179164A1LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOFSCHOLAR ROCK INC·Filed 2024·Application pending·0 cites
- 2579US2024374718A1Anti-pro/latent-myostatin antibodies and uses thereofSCHOLAR ROCK INC·Filed 2024·Application pending·0 cites
- 2678US2024016928A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2023·Application pending·0 cites
- 2777US12582712B2Method of making anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2022·Granted Mar 24, 2026·0 cites·8 claims
- 2877US11130803B2Isoform-selective TGFβ1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2019·Granted Sep 28, 2021·1 cites·10 claims
- 2977US2025215072A1Isoform-selective tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2024·Application pending·0 cites
- 3075US12173059B2LTBP complex-specific inhibitors of TGFβ and uses thereofSCHOLAR ROCK INC·Filed 2022·Granted Dec 24, 2024·0 cites·20 claims
- 3173US12577296B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2020·Granted Mar 17, 2026·0 cites·11 claims
- 3269US2023348583A1TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOFSCHOLAR ROCK INC·Filed 2023·Application pending·0 cites
- 3368US12338279B2Selective and potent inhibitory antibodies of myostatin activationSCHOLAR ROCK INC·Filed 2024·Granted Jun 24, 2025·0 cites·11 claims
- 3467US12281159B2TGFβ antibodies, methods and usesSCHOLAR ROCK INC·Filed 2021·Granted Apr 22, 2025·0 cites·26 claims
- 3567US2018022798A1Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2017·Application pending·0 cites
- 3667US2026035447A1Methods for treating metabolic diseases by inhibiting myostatin activationSCHOLAR ROCK INC·Filed 2025·Application pending·0 cites
- 3766US2018016332A1Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2017·Application pending·0 cites
- 3864US2017210798A1Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2017·Application pending·0 cites
- 3964US2022106390A1Methods for treating metabolic diseases by inhibiting myostatin activationSCHOLAR ROCK INC·Filed 2021·Application pending·0 cites
- 4064US2019209682A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2019·Application pending·0 cites
- 4163US12252531B2Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitorsSCHOLAR ROCK INC·Filed 2019·Granted Mar 18, 2025·0 cites·5 claims
- 4260US2018207267A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2018·Application pending·0 cites
- 4360US2025304669A1Rgmc-selective inhibitors and use thereofSCHOLAR ROCK INC·Filed 2025·Application pending·0 cites
- 4459US2021283166A1Use of myostatin inhibitors and combination therapiesSCHOLAR ROCK INC·Filed 2021·Application pending·0 cites
- 4558US2024301073A1LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOFSCHOLAR ROCK INC·Filed 2022·Application pending·0 cites
- 4658US2025257125A1HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOFSCHOLAR ROCK INC·Filed 2025·Application pending·0 cites
- 4757US2026035448A1Selective and potent inhibitory antibodies of myostatin activationSCHOLAR ROCK INC·Filed 2025·Application pending·0 cites
- 4857US2025326827A1Use of myostatin inhibitor for treating spinal muscular atrophySCHOLAR ROCK INC·Filed 2023·Application pending·0 cites
- 4956US12297262B2RGMC-selective inhibitors and use thereofSCHOLAR ROCK INC·Filed 2019·Granted May 13, 2025·0 cites·35 claims
- 5056US2024294623A1Tgf-beta inhibitors and therapeutic use thereofSCHOLAR ROCK INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →